Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035503 · ClinicalTrials.gov registry record · Phase 2
Multicenter Trial For Patients With Acute Crohn's Disease
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00035503: Completed Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00035503 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035503, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.
Interventions
- DRUG etiprednol dicloacetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01-31 |
| Est. Completion | 2004-01-31 |
| Phase | Phase 2 |
What the finished NCT00035503 record still lists
NCT00035503 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which etiprednol dicloacetate is the first listed.
NCT00035503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035503 about?
NCT00035503 is a clinical study titled "Multicenter Trial For Patients With Acute Crohn's Disease". The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.
What is the current status of trial NCT00035503?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-01-31. Estimated completion is 2004-01-31.
What interventions are being tested in trial NCT00035503?
The interventions under investigation include: etiprednol dicloacetate (DRUG).
Who is sponsoring clinical trial NCT00035503?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI